医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cerveau Technologies and Sinotau Pharmaceutical Group Announce Sinotau’s Achievement of a Major Milestone in China Strategy

2017年11月03日 AM01:40
このエントリーをはてなブックマークに追加


 

BOSTON

Sinotau Pharmaceuticals has announced today an agreement with HTA CO. LTD for launching a new β-amyloid imaging agent for Alzheimer’s disease in China.

“This agreement will greatly contribute to the successful launch of future products in China. It is expected that this new product will be used to treat patients by delivering the latest diagnostic technologies as well as contributing to developing therapies for Alzheimer’s disease. Sinotau Pharmaceuticals is devoted to develop the latest global nuclear medicine products for use in China,” says Xinsheng Xu, President and CEO of Sinotau Pharmaceuticals. “We are excited by this opportunity to cooperate with the largest Radiopharmaceutical production enterprise in China to accelerate the process of launching innovative drugs in the market and exploring pathways that strengthen and expand the radiopharmaceutical market in China.”

“HTA CO. LTD has considerably expanded the construction of a Radiopharmaceutical network and is focusing on the development and access of new technologies,” says Guomin Fan, president of HTA CO. LTD. “As a result of cooperating with Sinotau Pharmaceuticals there will be more opportunities to obtain novel technologies in the industry. Our collaboration will begin with encephalopathy and cardiovascular diseases widely known in the world.”

About Sinotau Pharmaceuticals

Sinotau Pharmaceuticals is listed on the NEEQ (stock code: 838851) and has a focus on developing the latest radiopharmaceuticals with integrated domestic and international resources. Sinotau has signed development rights for MK-6240 in China and other novel products for domestic purposes. Furthermore, through Sinotau’s partnership with Cerveau Technologies, Inc, collaborations have been developed with multiple pharmaceutical companies to support therapy development utilizing molecular imaging biomarkers.

About HTA CO. LTD

HTA CO. LTD is a company listed on the NEEQ (stock symbol: 430005). It is the biggest subsidiary of China Tongfu Stock Co., Ltd., focused on Radiopharmaceuticals and devoted to industrialize the application of nuclear technology. HTA CO. LTD owns the largest manufacturing portfolio and research network for radioactive isotopic preparation in China. Corresponding pharmaceutical sites and hospital centers have been established throughout the country.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171102006261/en/

CONTACT

Sinotau Pharmaceuticals
Xianghong Zou
18610482588
sinotau@sinotau.com
or
Cerveau
Technologies, Inc.

Rick Hiatt, 617-906-2715
RFhiatt@cerveautechnologies.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific
  • Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
  • Preceptis Medical宣布面向中国的B轮融资和全球增长战略
  • オクタファルマ、開発途上国の血友病患者を治療するために当社のNuwiq製剤3050万国際単位を寄付
  • Octapharma捐赠3050万国际单位该公司药品 Nuwiq以治疗发展中国家的血友病患者